ContiVir_logo_v02_BW.tiff
Enabling Bedside Manufacturing of Viral Vaccines & Gene Therapies

Currently, there is a serious lack of supply of virus particles for gene therapies and for vaccines in case of a pandemic emergency (influenza, coronavirus disease). Manufacturing capacity is limited to a handful of facilities relying on complicated, slow, and inefficient processes designed for specific products.

 

Expanding manufacturing capacity with traditional technologies will not improve the current situation:

It is estimated that a tenfold improvement in virus manufacturing is needed to enable the growth of the gene therapy market ($11 bn by 2025).

ContiVir is developing highly efficient virus production technologies than can be used for a wide range of virus-based products (around half of the current coronavirus vaccine candidates) and that have the potential to resolve the issues above by simplifying, miniaturizing, and de-centralizing manufacturing.

Learn more about Our Technologies.

TESTIMONIALS

"AT THE ONCOIMMUNOLOGY UNIT OF NAVARRABIOMED WE DEVELOP LENTIVIRUS-BASED CANCER IMMUNOTHERAPIES. TO ACCELERATE OUR RESEARCH, WE NEED A FAST, REPRODUCIBLE, AND EASY-TO-USE VIRUS PURIFICATION METHOD. WE TESTED CAPTUVIR TO PURIFY A 100 ML SAMPLE OF 0.45 µm-FILTERED LENTIVIRUS PREPARATIONS BOTH WITH AND WITHOUT FCS. COMPARED TO OTHER PURIFICATION METHODS SUCH AS PRECIPITATION OR CENTRIFUGATION THAT TAKE US ALMOST ONE DAY TO PERFORM, CAPTUVIR ALLOWED US TO CONCENTRATE OUR LENTIVIRUSES AROUND TEN TIMES WITH UP TO 70% RECOVERY IN ONLY ONE HOUR. WE PARTICULARLY LIKED THE FACT THAT USING CAPTUVIR WAS SIMPLE AND THE PURIFICATIONS WERE REPRODUCIBLE. WE WILL CONTINUE USING CAPTUVIR, ALSO FOR LARGER SAMPLE VOLUMES."

GRAZYNA KOCHAN AND DAVID ESCORS MURUGARREN, HEADS OF THE ONCOIMMUNOLOGY GROUP AT NAVARRABIOMED